(Q34569398)

3 August 2017

1 reference

title

Management of small cell lung cancer. (English)

1 reference

3 August 2017

Bruce E Johnson

1

1 reference

3 August 2017

publication date

1 March 2002

1 reference

Clinics in Chest Medicine

3 August 2017

published in

1 reference

3 August 2017

volume

23

1 reference

3 August 2017

issue

1

1 reference

3 August 2017

page(s)

225-239

1 reference

Ectopic adrenocorticotrophic (ACTH) syndrome and small cell carcinoma of the lung—assessment of clinical implications in patients on combination chemotherapy

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Prospective study of etoposide scheduling in combination chemotherapy for limited disease small cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Prophylactic Cranial Irradiation for Patients With Small-Cell Lung Cancer in Complete Remission

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Expression of the atrial natriuretic factor gene in small cell lung cancer tumors and tumor cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Teniposide and etoposide in previously untreated small-cell lung cancer: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

BRONCHOGENIC CARCINOMA WITH INAPPROPRIATE ANTIDIURETIC ACTIVITY IN PLASMA AND TUMOR

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Stereotactic radiosurgery for the treatment of brain metastases. Results of a single institution series

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Gender and Histologic Type Variations in Smoking-Related Risk of Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Secretion of atrial natriuretic peptide and vasopressin by small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Increasing use of bronchoscopic needle aspiration to diagnose small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermont

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Outcome of patients with small-cell lung cancer: effect of changes in staging procedures and imaging technology on prognostic factors over 14 years.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Small cell carcinoma versus other lung malignancies: diagnosis by fine-needle aspiration cytology

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Small cell lung cancer: current status of new chemotherapeutic agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Biosynthesis of vasopressin in vitro and ultrastructure of a bronchogenic carcinoma. Patient with the syndrome of inappropriate secretion of antidiuretic hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

The role of systemic chemotherapy in the treatment of brain metastases from small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Surgery for combined type small cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Positron emission tomography in the staging of small-cell lung cancer : a preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Histopathologic classification of small cell lung cancer. Changing concepts and terminology.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Histopathologic classification of small cell carcinoma of the lung. Comments based on an interobserver examination

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Asymptomatic brain metastases (BM) in small cell lung cancer (SCLC): MR-imaging is useful at initial diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Second-line chemotherapy and its evaluation in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Serial fiberoptic bronchoscopy during chemotherapy for small cell carcinoma of the lung: early detection of patients at high risk of relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Surgical results for small cell lung cancer based on the new TNM staging system. Thoracic Surgery Study Group of Osaka University, Osaka, Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Results of preoperative mediastinoscopy for small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Effect of tobacco smoking on various histological types of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Second lung cancers in patients after treatment for an initial lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

A prospective study of patients with lung cancer and hyponatremia of malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Data on potential cures, chronic toxicities, and late relapses after a five- to eleven-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Risk of second aerodigestive cancers increases in patients who survive free of small-cell lung cancer for more than 2 years

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Neurologic, computed cranial tomographic, and magnetic resonance imaging abnormalities in patients with small-cell lung cancer: further follow-up of 6- to 13-year survivors.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Female patients with small cell lung cancer live longer than male patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Value and accuracy of cytology in addition to histology in the diagnosis of lung cancer at flexible bronchoscopy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Atrial natriuretic peptide in patients with the syndrome of inappropriate antidiuretic hormone secretion and with diabetes insipidus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Prognostic factors and prognostic staging system for small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

New chemotherapy agents for small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Quantal components of end-plate potentials in the myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

The role of prophylactic brain irradiation in limited stage small cell lung cancer: clinical, neuropsychologic, and CT sequelae.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Comparison of three treatment options for single brain metastasis from lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Late neurological complications after prophylactic cranial irradiation in patients with small-cell lung cancer: the Toronto experience

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

The frequency and clinical biology of the ectopic hormone syndromes of small cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Response of brain metastases from lung cancer to systemic chemotherapy with carboplatin and etoposide.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Hu antigens: Reactivity with hu antibodies, tumor expression, and major immunogenic sites

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Expression of a photoreceptor protein, recoverin, as a cancer-associated retinopathy autoantigen in human lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Lambert-Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Intensive weekly chemotherapy for good-prognosis patients with small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

COMMENTARY: Phase II Trial Design Considerations for Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Revisions in the International System for Staging Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Diagnosis and significance of liver metastases in small cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

A phase II trial of cisplatin and prolonged administration of oral etoposide in extensive-stage small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Influence of surgical resection prior to chemotherapy on the long-term results in small cell lung cancer. A study of 150 operable patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

A meta-analysis of thoracic radiotherapy for small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy--a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Long term results of surgery and chemotherapy in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Bronchogenic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Small-cell carcinoma of the lung: derivation of a prognostic staging system

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Predictors of radiation response in lung cancer. A clinico-pathobiological analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Radiation therapy for chest recurrences following induction chemotherapy in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Maintenance chemotherapy for small cell lung cancer: a critical review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Cushing's syndrome associated with ectopic corticotropin production and small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Specificity of calcium channel autoantibodies in Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Ectopic atrial natriuretic peptide production in small cell lung cancer with the syndrome of inappropriate antidiuretic hormone secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Survival after resection of small cell carcinoma of the bronchus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Survival in small cell lung carcinoma after surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Small cell lung cancer cell lines secrete predominantly ACTH precursor peptides not ACTH.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

ACTH precursors characterize the ectopic ACTH syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Treatment of small-cell lung cancer with an alternating chemotherapy regimen given at weekly intervals: a Southwest Oncology Group pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Cancer-associated retinopathy (CAR syndrome) with antibodies reacting with retinal, optic-nerve, and cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Small-cell lung cancer: importance of fiberoptic bronchoscopy in the evaluation of complete remission.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

A preliminary report: concurrent twice-daily radiotherapy plus platinum-etoposide chemotherapy for limited small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Obstructive atelectasis in patients with small cell lung cancer. Incidence and response to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Clinical diagnostic application of 111In-DTPA-octreotide scintigraphy in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Long term survival of small cell lung cancer patients after chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Sequelae in long-term survivors of small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Inhibition of calcium currents and exocytosis by Lambert-Eaton syndrome antibodies in human lung cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): The role of sex as a predictor for survival

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

Small cell lung cancer with and without superior vena cava syndrome: A multivariate analysis of prognostic factors in 408 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900070-4

7 January 2021

10.1016/S0272-5231(03)00070-4

Identifiers

DOI

1 reference

3 August 2017

1 reference